Switch to:
More From Other Websites
Alexion Pharmaceuticals' Rebound To Continue -Vetr Crowd Aug 26 2016
What Do Analysts Think about BioMarin’s Return Potential? Aug 26 2016
How Much Did BioMarin’s Lead Drug Vimizim Earn in 1H16? Aug 26 2016
Tesla Tops Forbes' 2016 List of Most Innovative Companies (TSLA, CRM) Aug 25 2016
Biotech Stocks: Trouble Ahead, Trouble Behind? Aug 19 2016
Horizon’s Orphan Drug Business Faces These Opportunities Aug 19 2016
Spiros Segalas on Alexion Pharmaceuticals Aug 18 2016
ETF’s with exposure to Alexion Pharmaceuticals, Inc. : August 18, 2016 Aug 18 2016
What Are the Opportunities for Horizon in 2016? Aug 18 2016
How to Play a Nasdaq Breakout Aug 12 2016
Are High Composite Ratings An Automatic 'Buy' Signal? No. Here's Why Aug 10 2016
AstraZeneca bets another $140 million on Moderna's 'messenger' drugs Aug 10 2016
Biotech Stocks: Blame Gilead? Aug 09 2016
What Do Analysts Recommend for Regeneron after 2Q16 Earnings? Aug 09 2016
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events Aug 08 2016
What Are Analysts Recommending for Shire? Aug 08 2016
An Update on Shire’s Upcoming Milestones Aug 05 2016
New Strong Sell Stocks for August 5th Aug 05 2016
What’s behind Shire’s 2Q16 Earnings Surprise? Aug 04 2016
ETF’s with exposure to Alexion Pharmaceuticals, Inc. : August 4, 2016 Aug 04 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK